 |
|
|
| |
Switching From a Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to a Tenofovir Alafenamide (TAF)-Based Regimen: Data in Virologically Suppressed Adults Through 48 Weeks of Treatment
|
| |
| |
Reported by Jules Levin
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22,
Vancouver, Canada BC
Anthony Mills,1 Jaime Andrade-Villanueva,2 Giovanni DiPerri,3 Jan Van Lunzen,4 Ellen Koenig,5 Richard Elion,6 Matthias Cavassini,7 Jose Valdez-Madruga,8 Jason Brunetta,9 David Shamblaw,10 Edwin DeJesus,11 Andrew Plummer,12 YaPei Liu,12 and Scott McCallister,12 on behalf of the Gilead GS-US-292-0109 Study Team
1Southern California Men's Medical Group, Los Angeles, CA, USA; 2Hospital Civil de Guadalajara, Mexico; 3Amedeo di Savoia Hospital, Turin, Italy; 4Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany; 5Instituto Dominicano de Estudios Virologicos, Santo Domingo, Dominican Republic; 6Whitman-Walker Health, Washington, DC, USA; 7Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland; 8Centro de Referencia e Treinamento em DST/AIDS, Sao Paolo, Brazil; 9Maple Leaf Research, Toronto, Canada; 10La Playa Medical Group, San Diego, CA, USA; 11Orlando Immunology Center, Orlando, FL, USA; 12Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
